Mark Kutner, MD
Internal Medicine · Miami, FLNPI 1104875277
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,477 of the $33,067 with a category attached, or 65.0%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2019 at $9,572 and has fallen 59.4% since, to $3,889 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,020 payments — averaging $32.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7K
- Modernatx, Inc.$3K
- Pfizer$3K
- Amgen$3K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- plus $12K from 54 others
Across 1,819 payments — averaging $19,771 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$11.9M
- Modernatx, Inc.$8.7M
- Bavarian Nordic A/s$4.7M
- Janssen Research & Development, LLC$2.2M
- Johnson & Johnson$2M
- Pfizer$1.2M
- plus $5.3M from 21 others
What the payments were for
- Travel & lodging$11,39734%
- Food & beverage$21,47765%
- Education$1931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR - 13$799
- TRELEGY ELLIPTA$492
- Vascepa$369
- Ozempic$353
- Repatha$237
- Tymlos$125
- RYBELSUS$125
- DEXCOM G7 GSS (161)$125
- ANORO ELLIPTA$122
- NOCDURNA$119
- MOUNJARO$118
- EVENITY$115
How this compares
$33,067 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $52,915 |
| MounjaroTirzepatide | 39 | $49,274 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $48,232 |
| EliquisApixaban | 38 | $46,501 |
| JardianceEmpagliflozin | 36 | $34,296 |
| VascepaIcosapent Ethyl | 31 | $20,401 |
| RybelsusSemaglutide | 11 | $17,956 |
| FarxigaDapagliflozin Propanediol | 15 | $13,265 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 13 | $3,907 |
| Rosuvastatin Calcium | 141 | $2,135 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $2,007 |
| SynthroidLevothyroxine Sodium | 16 | $1,764 |
| Testosterone | 12 | $1,733 |
| Ezetimibe | 41 | $1,252 |
| Atorvastatin Calcium | 130 | $1,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,338 | $70,87161 claims |
| GSKTrelegy Ellipta, Arexvy | $1,712 | $52,13968 claims |
| Lilly USA, LLCMounjaro | $1,866 | $49,27439 claims |
| PfizerEliquis | $3,108 | $46,50138 claims |
| Boehringer IngelheimJardiance | $565 | $34,29636 claims |
| AstraZenecaFarxiga | $759 | $13,26515 claims |
| AbbVieSynthroid | $952 | $1,76416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.